# Agaricus Blazei Murill in Patients With Multiple Myeloma

> **NCT00970021** · PHASE2 · COMPLETED · sponsor: **Ullevaal University Hospital** · enrollment: 39 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DIETARY_SUPPLEMENT:** Intake of 60 ml placebo daily in addition to chemotherapy
- **DIETARY_SUPPLEMENT:** Intake of 60 ml agaricus daily in addition to chemotherapy

## Key facts

- **NCT ID:** NCT00970021
- **Lead sponsor:** Ullevaal University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-05
- **Final completion:** 2014-02
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2014-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00970021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00970021, "Agaricus Blazei Murill in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00970021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*